AbbVie (ABBV), Abbott (ABT) Win Dismissal of AndroGel, Humira Racketeering Suit

AbbVie (NYSE: ABBV) and Abbott Labs (NYSE: ABT) won a lawsuit over claims of racketeering with respect to the Humira arthritis drug and AndroGel testosterone drug.

According to Reuters, U.S. District Judge Robert Dow said the New England Carpenters Health and Welfare Fund didn't show that AbbVie and Abbott joined together with retail pharmacies and intermediaries to maximize sales of the two drugs.

There will still be litigation with respect to remaining state law claims in the suit, which Dow said he might not have jurisdiction over.

Sales of Humira and AndroGel were $5.93 billion and $472 million for the first-half of 2014.

AbbVie and Abbott are flat in early trading.

You May Also Be Interested In

• FDA: working with AbbVie (ABBV) to identify, investigate and remove suspected counterfeit Botox products found in the US
• Takeda (TAK) U.S. FDA Approves Subcutaneous Administration of ENTYVIO
• Q1 earnings buy list: Morgan Stanley picks Nvidia, Amazon and these 10 stocks